News

AstraZeneca: won t profit from COVID-19 vaccine in pandemic

AstraZeneca: won t profit from COVID-19 vaccine in pandemic
Health
LONDON -- Pharmaceutical company AstraZeneca repeated its promise not to profit from a COVID-19 vaccine during the pandemic as it reported it was on track with late-stage trials for the treatment.

Such promises were boosted by strong sales across its range of treatments during lockdown. Sales jumped by 14% to US$12.6 billion in the first six months of 2020 and were helped by strong trading in new medicines, as well as cancer and respiratory medication.

Despite the good earnings, CEO Pascal Soriot said he remained cautious amid the uncertainty of the pandemic.

"If we have learned one thing with this virus, it is that it is unpredictable," he said. "And so we need to remain cautious."

He said the supply chain was on track to make 2 billion doses of the vaccine at a few dollars a dose. It also concluded three more deals for distribution -- should the vaccine work.

"We felt, there (is) a time in life when companies need to step up and make a contribution," he said, adding that a vaccine needed to be accessible to as many people as possible.

"This is the kind of time in history when ... humankind is really threatened as a whole," he said.

The cost of making the vaccine, which was developed by Oxford University, is expected to be offset by funding from the governments.

AstraZeneca has struck a number of deals around the world to supply the experimental COVID-19 vaccine, which has shown promise in early testing. The Anglo-Swedish company recently completed agreements with the United States, Britain, the European Union, the Coalition for Epidemic Preparedness Innovations, a public-private-charitable partnership based in Norway, and Gavi, the Vaccine Alliance, another public-private partnership headquartered in Geneva.

It has also reached a licensing agreement with Serum Institute of India to supply low-and-middle-income countries and agreements with R-Pharm in Russia and SK Biopharmaceuticals Co., Ltd in the Republic of Korea "to manufacture and export for other global markets."
Read more on CTVnews
News Topics :
Similar Articles :
World
Last month, AstraZeneca said it could manufacture one billion doses, that it is developing with scientists at Oxford University. On Thursday, it signed two deals, including one backed by Bill...
World
ROME Reuters AstraZeneca Plc has signed a contract with European governments to supply the region with its potential vaccine against the coronavirus, the British drugmaker’s latest deal to pledge...
World
LONDON Pharma giant AstraZeneca struck a deal Saturday with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of an experimental COVID 19 vaccine, as efforts to boost...
World
LONDON Drug maker AstraZeneca secured its first agreements Thursday for 400 million doses of a COVID 19 vaccine, bolstered by an investment from the U.S. vaccine agency. The Anglo Swedish company...
World
LONDON Politicians and public health leaders have publicly committed to equitably sharing any coronavirus vaccine that works, but the top global initiative to make that happen may allow rich...